← Back to Clinical Trials
Recruiting NCT06699433

NCT06699433 Artificial Intelligence-driven Virtual Standardized Pediatric Patients Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06699433
Status Recruiting
Phase
Sponsor Southern Medical University, China
Condition Pneumococcal Pneumonia
Study Type INTERVENTIONAL
Enrollment 459 participants
Start Date 2024-12
Primary Completion 2024-12

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Virtual standardized patients (VSPs)Case teaching manualsCase teaching videos

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 459 participants in total. It began in 2024-12 with a primary completion date of 2024-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Background: China's healthcare system for children faces significant challenges, particularly due to the limited pediatric service capacity of primary healthcare institutions. A shortage of effective and accessible training tools for primary care doctors further hinders progress in addressing this gap. Technological advancements, especially in artificial intelligence, offer a potential solution to improve pediatric care. Artificial intelligence-driven virtual standardized patients (VSPs), leveraging internet and virtual simulation technologies, simulate clinical cases with specific disease characteristics, providing an innovative, efficient, and flexible training method. VSPs are increasingly utilized in medical education, clinical reasoning, and licensure exams. This study focuses on using VSPs to improve the management of common pediatric conditions, which are major health concerns for children and impose significant psychological and financial burdens on families. Methods: This study will involve a three-arm randomized controlled trial to evaluate the effectiveness of a virtual pediatric standardized patient platform in enhancing primary care doctors' management of common pediatric diseases. At least 459 participants, including general practitioners, internal medicine practitioners, surgeons, and pediatricians from more than 10 provinces across China, will be randomly assigned to one of three groups: the virtual patient platform group, the case teaching manual group, or the case teaching video group. Five virtual patient cases covering pneumococcal pneumonia, rotavirus enteritis with hypovolemic shock, hand-foot-and-mouth disease, acute appendicitis, and respiratory failure will be developed, along with corresponding case teaching materials. After a two-week learning period, participants' disease management abilities will be assessed using clinical vignettes. The primary outcome is adherence to best clinical practice guidelines, categorized into full adherence, partial adherence, and nonadherence. Discussion: This study aims to leverage artificial intelligence for capacity enhancement, targeting the shortcomings of primary care pediatrics and using VSP to help enhance primary care pediatrics capacity. It is a randomized controlled trial involving over 300 primary healthcare institutions across more than 10 provinces in China, ensuring broad and representative participation from both developed and underdeveloped regions.

Eligibility Criteria

1. Inclusion and Exclusion Criteria for Research Institutions Inclusion Criteria: * Primary and secondary hospitals * Community health centers (stations) and clinics, as well as township health centers and village health clinics Exclusion Criteria: * Specialized medical institutions (such as specialized hospitals and dental clinics) * Public health prevention and treatment institutions (such as tuberculosis prevention centers) * Ethnic medicine institutions (such as Mongolian and Tibetan hospitals) * Hospitals above the secondary level * Hospitals that have not yet been graded (due to their short establishment time and potentially unstable operations) 2. Inclusion and exclusion criteria for research subjects Inclusion Criteria: * Practicing (assistant) doctors and rural doctors working in medical institutions that meet the above conditions * With a scope of practice only including general practice, internal medicine, surgery, and pediatrics Exclusion Criteria: -None

Contact & Investigator

Central Contact

Luo

✉ huanyuanluo33@gmail.com

📞 +86-19566890018

Principal Investigator

Yao Zhao, Doctor

PRINCIPAL INVESTIGATOR

National Clinical Research Center for Child Health and Disorders, Chongqing, China

Frequently Asked Questions

Who can join the NCT06699433 clinical trial?

This trial is open to participants of all sexes, studying Pneumococcal Pneumonia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06699433 currently recruiting?

Yes, NCT06699433 is actively recruiting participants. Contact the research team at huanyuanluo33@gmail.com for enrollment information.

Where is the NCT06699433 trial being conducted?

This trial is being conducted at Guiyang, China, Fuzhou, China, Yisa, China.

Who is sponsoring the NCT06699433 clinical trial?

NCT06699433 is sponsored by Southern Medical University, China. The principal investigator is Yao Zhao, Doctor at National Clinical Research Center for Child Health and Disorders, Chongqing, China. The trial plans to enroll 459 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology